Crown Laboratories, Inc. (“Crown”) and Revance Therapeutics, Inc. (NASDAQ: RVNC) (“Revance”), announce that, on January 17, 2025, they amended their previously announced Amended and Restated Merger Agreement (the “Second Amendment,” together with the Amended and Restated Merger Agreement, dated December 7, 2024, the “A&R Merger Agreement”). Under the terms of the Second Amendment, which has been unanimously approved by the Revance Board of Directors, Revance’s stockholders will receive $3.65 per share of common stock, par value $0.001 per share (each, a “Share”) in cash, without interest and less any applicable tax withholding, representing $0.55 or 17% per share more than the prior offer price.
Read the full article: Crown Laboratories and Revance Amend the A&R Merger Agreement //
Source: https://www.businesswire.com/news/home/20250121493847/en/Crown-Laboratories-and-Revance-Amend-the-AR-Merger-Agreement-to-Increase-Offer-Price-to-3.65-per-Share-and-Extend-Existing-Tender-Offer